Last updated: September 1, 2026
Lesinurad failed commercially despite FDA and European approvals because its efficacy depended on combination use, its renal-safety profile constrained prescribing, and its market entered after established urate-lowering therapies. AstraZeneca withdrew Zurampic from the U.S. market in 2019, while the European authorization for Zurampic and Duzallo was later withdrawn at the company’s request. Lesinurad has no biosimilar pathway, but generic-entry risk remains relevant because it is a small-molecule drug with limited commercial protection and no durable franchise.
What is lesinurad and how was it commercialized?
Lesinurad is a selective uric acid reabsorption inhibitor that blocks the URAT1 transporter. It was developed for chronic hyperuricemia associated with gout and was intended for use with a xanthine oxidase inhibitor such as allopurinol or febuxostat.
AstraZeneca acquired Ardea Biosciences in 2012 for approximately $1.26 billion, gaining rights to lesinurad and other Ardea assets. The transaction placed lesinurad within AstraZeneca’s cardiovascular and metabolic-disease portfolio before launch.
| Product |
Active ingredient |
Sponsor |
Indication |
Regulatory status |
| Zurampic |
Lesinurad |
AstraZeneca |
Hyperuricemia associated with gout, with an XOI |
FDA approved Dec. 22, 2015 |
| Duzallo |
Lesinurad/allopurinol |
Ironwood Pharmaceuticals, under license from AstraZeneca |
Hyperuricemia associated with gout in patients not controlled on allopurinol alone |
FDA approved Aug. 22, 2017 |
| Zurampic |
Lesinurad |
AstraZeneca |
Combination therapy for gout |
European authorization later withdrawn |
| Lesinurad generic |
Lesinurad |
No established major U.S. generic market |
Small-molecule equivalent |
No material commercial generic presence identified |
The FDA label prohibited lesinurad monotherapy. Zurampic had to be administered with an XOI, and Duzallo combined lesinurad with allopurinol in a single tablet. This limited the addressable market relative to conventional allopurinol and febuxostat prescriptions. (U.S. Food and Drug Administration [FDA], 2015, 2017)
When did lesinurad lose market exclusivity?
Lesinurad’s commercial exclusivity effectively ended when AstraZeneca stopped marketing Zurampic in the United States in 2019, before a large generic market developed. The patent position did not translate into sustained branded demand.
The principal U.S. patent estate included composition and pharmaceutical-composition patents associated with lesinurad. Public Orange Book records identified U.S. Patent No. 8,541,446 and U.S. Patent No. 9,266,856 in connection with lesinurad products. The reported patent-term horizon extended into the late 2020s, subject to patent-term adjustment and product-specific listing status. (FDA, Orange Book)
| Milestone |
Date |
| Ardea acquired by AstraZeneca |
June 2012 |
| FDA approval of Zurampic |
Dec. 22, 2015 |
| U.S. commercial launch |
2016 |
| FDA approval of Duzallo |
Aug. 22, 2017 |
| AstraZeneca U.S. withdrawal of Zurampic |
2019 |
| European authorization withdrawal process |
2020 |
| Practical commercial exclusivity |
Ended with market withdrawal rather than successful patent expiry |
A regulatory exclusivity period did not protect lesinurad from weak uptake. The principal commercial issue was demand, not the immediate arrival of a generic competitor.
What patents protect lesinurad and its formulations?
The lesinurad patent estate covered the active compound, pharmaceutical compositions, and use of the drug for hyperuricemia and gout. Composition patents generally provide the strongest protection because they can cover the molecule across multiple formulations and indications.
Composition patents
U.S. Patent No. 8,541,446 is associated with substituted pyrazole compounds, including lesinurad-related chemical matter. Its expected term extended into the late 2020s based on the underlying priority and U.S. patent-term rules.
U.S. Patent No. 9,266,856 was also listed in connection with lesinurad products. Its relevance included pharmaceutical compositions and product protection associated with the marketed drug. Exact enforceability depended on claim scope, terminal disclaimers, patent-term adjustment, and the specific product at issue.
Formulation patents
Duzallo created a separate formulation strategy by combining lesinurad and allopurinol in a fixed-dose tablet. The commercial objective was to improve adherence and provide a differentiated product against separate tablets.
The formulation strategy had limits:
- The combination was dependent on a patient already requiring allopurinol-based urate lowering.
- Allopurinol was inexpensive and widely available as a generic.
- Physicians could prescribe the two active ingredients separately.
- The fixed-dose product did not remove lesinurad’s renal-monitoring requirements.
- Duzallo entered after Zurampic had already developed limited market momentum.
Formulation patents can delay substitution when they cover a commercially important dosage form. They have less value when the underlying product has low demand and the same clinical components can be prescribed separately.
Method-of-use patents
Lesinurad patents and regulatory labeling were directed to treatment of hyperuricemia associated with gout, generally as add-on therapy to an XOI. Method-of-use claims could support enforcement against a generic label that directly encouraged the patented combination use.
That protection was commercially narrow. Allopurinol and febuxostat already provided the foundational treatment, and the FDA label’s restriction against lesinurad monotherapy limited the scope of any use-based franchise.
What was the FDA regulatory status of lesinurad?
The FDA approved Zurampic in December 2015 for use with an XOI in patients with gout-associated hyperuricemia. The approval required renal monitoring and included a warning concerning acute renal failure, particularly when lesinurad was used without an XOI or when renal function was impaired.
The FDA approved Duzallo in 2017 as a fixed-dose combination of lesinurad and allopurinol. The product targeted patients whose hyperuricemia was not adequately controlled with allopurinol alone.
The regulatory profile created several market restrictions:
- Lesinurad could not be used as monotherapy.
- Renal function had to be assessed before and during treatment.
- Use was unsuitable for patients with significant renal impairment.
- The risk-benefit profile was less attractive for patients controlled on inexpensive allopurinol.
- The drug competed against established care pathways rather than replacing a poorly served treatment.
The European Medicines Agency authorized Zurampic and Duzallo for combination use but later recorded withdrawal of the marketing authorizations at the company’s request. The withdrawal was linked to commercial considerations rather than a broad regulatory finding that eliminated the molecule’s therapeutic value. (European Medicines Agency [EMA], 2020)
How did lesinurad sales perform?
Lesinurad did not become a material revenue contributor for AstraZeneca. AstraZeneca’s annual reports did not identify Zurampic as a major growth product, and reported sales were immaterial relative to the company’s oncology, respiratory, cardiovascular, and biologics franchises. The company discontinued U.S. commercialization after limited market uptake.
The financial trajectory was therefore:
| Period |
Commercial development |
Financial implication |
| 2012-2015 |
Acquisition and clinical development |
Significant upfront investment through the Ardea transaction and launch preparation |
| 2016 |
U.S. launch of Zurampic |
Initial sales remained small |
| 2017 |
Duzallo approval and Ironwood commercialization |
Product expansion failed to generate a meaningful franchise |
| 2018 |
Continued limited uptake |
Revenue remained nonmaterial to AstraZeneca |
| 2019 |
U.S. withdrawal |
Future branded U.S. revenue effectively ended |
| 2020 onward |
European authorization withdrawal and limited availability |
No significant global branded growth platform |
AstraZeneca’s decision to withdraw Zurampic demonstrates the gap between regulatory approval and commercial value. A product can obtain approval, hold active patents, and still have negative or insufficient return on invested capital when adoption is weak and postmarketing obligations are costly.
Ironwood’s involvement with Duzallo also illustrates the difficulty of licensing a differentiated gout product. The fixed-dose combination addressed adherence, but the product remained tied to lesinurad’s renal-safety constraints and to the low cost of generic allopurinol.
Why did lesinurad underperform commercially?
Limited clinical differentiation
Allopurinol remained the dominant first-line urate-lowering therapy. Febuxostat offered another established option for patients who were intolerant of or inadequately controlled on allopurinol. Lesinurad was positioned as an add-on rather than a replacement.
That positioning required physicians to identify patients with persistent hyperuricemia despite XOI therapy and then accept additional renal monitoring. The eligible population was narrower than the overall gout population.
Renal-safety concerns
The risk of acute renal failure was a major prescribing barrier. The risk increased when lesinurad was used alone, which the FDA label prohibited. Even in combination therapy, the need for kidney-function monitoring complicated routine use.
Patients with gout frequently have chronic kidney disease, hypertension, diabetes, or cardiovascular disease. These comorbidities reduced the number of patients considered suitable for lesinurad.
Reimbursement and pricing pressure
Lesinurad entered a market where generic allopurinol was inexpensive and widely available. Payers had limited incentive to cover a premium add-on product when serum urate could often be managed through dose adjustment, adherence interventions, or alternative XOI therapy.
Fixed-dose Duzallo improved convenience but did not eliminate the cost comparison with separate generic tablets.
Weak launch timing
Zurampic entered after years of treatment familiarity with allopurinol and febuxostat. AstraZeneca had to change prescribing behavior in a chronic disease with a relatively low level of treatment escalation.
The company also faced competition from other emerging gout therapies, including pegloticase for refractory disease and established anti-inflammatory treatments for flares. Lesinurad did not occupy the same treatment niche as pegloticase, but the broader gout market had competing approaches for different patient segments.
Were there Paragraph IV challenges or patent lawsuits involving lesinurad?
No major publicly reported U.S. Paragraph IV litigation became a defining commercial event for Zurampic or Duzallo. The products were withdrawn or commercially weakened before generic competition became the central value driver.
The absence of prominent litigation does not mean that the patents lacked technical scope. It indicates that the market opportunity was insufficient to create a large, visible generic challenge during the key commercial period.
The likely generic-entry path would have involved:
- A therapeutic-equivalence application for lesinurad tablets.
- Paragraph IV certifications against Orange Book-listed patents.
- Potential challenges to composition, formulation, or method-of-use claims.
- A separate analysis for fixed-dose lesinurad/allopurinol tablets.
- Commercial launch decisions driven by reimbursement and demand rather than patent expiry alone.
Because lesinurad’s branded market had already contracted sharply, a generic entrant would face limited upside. The principal barrier was market size, not only patent enforcement.
What generic entry risks exist for lesinurad?
Lesinurad is a small molecule, so an ANDA-based generic pathway is available in principle. Biosimilar risk does not apply because lesinurad is not a biologic.
| Risk category |
Assessment |
| Biosimilar competition |
Not applicable |
| Small-molecule ANDA competition |
Legally available |
| Composition-patent risk |
Potentially relevant through the late 2020s, depending on claim and term |
| Formulation-patent risk |
Relevant to fixed-dose lesinurad/allopurinol products |
| Method-of-use risk |
Narrow because the FDA label requires combination use |
| Commercial attractiveness |
Low |
| Branded defense value |
Limited after withdrawal |
| Manufacturing barrier |
Moderate technical barrier, low strategic barrier |
Manufacturing lesinurad requires control of chemical synthesis, impurities, polymorphic form, formulation consistency, and bioequivalence. These are manageable for experienced generic manufacturers and do not create a biologic-scale manufacturing moat.
For a generic company, the key question is not whether lesinurad can be made. It is whether payers, physicians, and patients will support a sufficient volume after accounting for regulatory, legal, and launch costs.
How strong is the lesinurad patent estate?
The estate was technically meaningful but commercially weak.
Strengths
- Composition protection extended beyond the initial launch period.
- The active compound had identifiable Orange Book-listed patent coverage.
- Fixed-dose combination claims could create a separate barrier for Duzallo.
- Combination-use patents aligned with the approved indication.
Weaknesses
- The FDA label sharply constrained use.
- Commercial demand was low.
- A generic could potentially target separate lesinurad tablets without reproducing every feature of Duzallo.
- Method-of-use enforcement would depend on the scope of the generic label and actual prescribing.
- Withdrawal reduced the economic value of enforcement.
Patent strength should therefore be rated as moderate from a technical standpoint and low from an investment standpoint. The estate could delay or complicate entry, but it could not create a profitable market after the branded franchise lost commercial traction.
Which companies challenged or competed with lesinurad?
No company became a major branded lesinurad challenger in the U.S. The competitive landscape consisted primarily of alternative urate-lowering therapies.
| Company or product |
Role in the market |
| Teva, Mylan/Viatris, Sandoz and other generic manufacturers |
Generic allopurinol competition |
| Takeda’s Uloric/febuxostat franchise |
Alternative XOI therapy |
| Horizon’s Krystexxa/pegloticase |
Refractory or uncontrolled chronic gout |
| AstraZeneca |
Zurampic sponsor and original commercializer |
| Ironwood Pharmaceuticals |
Duzallo commercialization partner |
The strongest competitive pressure came from generic allopurinol, not from a direct branded URAT1 inhibitor. Generic allopurinol reduced the economic justification for adding an expensive branded uricosuric agent.
What licensing deals affected lesinurad?
AstraZeneca’s acquisition of Ardea was the central transaction. It gave AstraZeneca global control of lesinurad and related development assets.
Ironwood Pharmaceuticals later commercialized Duzallo in the United States under an agreement with AstraZeneca. The partnership attempted to extend the franchise through a fixed-dose product rather than relying only on Zurampic.
The deal structure created strategic logic but limited financial value. AstraZeneca gained a commercial partner, while Ironwood gained access to a differentiated gout product. Neither company achieved a material long-term revenue stream from the program.
What generic launch scenarios remain possible?
Three scenarios define the residual market.
Scenario 1: No meaningful generic launch
This is the most commercially rational scenario when the branded product has been withdrawn and payer demand is weak. Patent expiry alone does not guarantee entry.
Scenario 2: Limited specialty generic launch
A generic manufacturer could enter for selected patients with refractory hyperuricemia, especially where physicians value the URAT1 mechanism or where supply is available through specialty pharmacies.
Scenario 3: Fixed-dose combination re-entry
A manufacturer could seek approval for a lesinurad/allopurinol combination. This would face narrower demand than a standalone tablet because patients and prescribers can use separate products. The combination may also encounter formulation-patent and labeling issues.
None of these scenarios supports a large revenue opportunity without a new clinical positioning, a major price reduction, or evidence showing meaningful benefit in a well-defined renal-function subgroup.
How does lesinurad compare with febuxostat and pegloticase?
| Attribute |
Lesinurad |
Febuxostat |
Pegloticase |
| Drug type |
Small-molecule URAT1 inhibitor |
Small-molecule XOI |
Biologic uricase |
| Typical role |
Add-on to XOI |
Alternative XOI |
Refractory chronic gout |
| Monotherapy |
Not permitted under FDA labeling |
Yes |
Used as specialized therapy |
| Administration |
Oral |
Oral |
Intravenous infusion |
| Main barrier |
Renal safety and narrow positioning |
Cardiovascular safety concerns and generic competition |
Cost, infusion burden, immunogenicity |
| Manufacturing barrier |
Moderate |
Moderate |
High |
| Generic or biosimilar pathway |
ANDA generic |
ANDA generic |
Biosimilar pathway |
| Commercial outlook |
Discontinued and limited |
Established, though pressured |
Specialty-market product |
Lesinurad had a simpler oral delivery system than pegloticase but lacked the latter’s role in severe refractory disease. Compared with febuxostat, lesinurad required combination treatment and faced a narrower treatment pathway.
Key Takeaways
- Lesinurad was approved by the FDA in 2015 as Zurampic and in 2017 as Duzallo.
- AstraZeneca acquired Ardea Biosciences for approximately $1.26 billion, making lesinurad a major strategic asset at the time of acquisition.
- The product underperformed because it was an add-on therapy, could not be used alone, required renal monitoring, and competed with inexpensive generic allopurinol.
- AstraZeneca withdrew Zurampic from the U.S. market in 2019.
- European authorizations for Zurampic and Duzallo were later withdrawn at the company’s request.
- The U.S. patent estate included Orange Book-listed U.S. Patent Nos. 8,541,446 and 9,266,856, with reported terms extending into the late 2020s.
- No major Paragraph IV litigation shaped the product’s commercial history.
- Biosimilar risk is irrelevant because lesinurad is a small molecule.
- Generic entry is legally possible but commercially unattractive without a new market opportunity.
- The lesinurad patent estate was stronger technically than financially.
FAQs
Is lesinurad still available in the United States?
AstraZeneca discontinued U.S. commercial availability of Zurampic in 2019. No large active U.S. branded market remains.
Was Duzallo more successful than Zurampic?
No material evidence shows that Duzallo created a durable commercial franchise. Its fixed-dose formulation addressed adherence but retained lesinurad’s combination-use and renal-safety limitations.
Does lesinurad have biosimilar competition?
No. Lesinurad is a chemically synthesized small molecule and would be challenged through the FDA ANDA pathway, not the biosimilar pathway.
What was the largest commercial obstacle for lesinurad?
The largest obstacle was its narrow clinical position as an add-on to an XOI in a market dominated by generic allopurinol. Renal-safety concerns further reduced prescribing.
Could a generic company relaunch lesinurad?
A generic relaunch is legally possible, but the market opportunity is limited. Commercial success would require a defined patient population, payer coverage, reliable supply, and pricing sufficient to justify regulatory and manufacturing costs.
References
-
AstraZeneca. (2012). AstraZeneca to acquire Ardea Biosciences for $1.26 billion. AstraZeneca investor materials.
-
AstraZeneca. (2016-2019). Annual reports and financial statements. AstraZeneca.
-
European Medicines Agency. (2020). Zurampic: EPAR and European Commission authorization information. EMA.
-
U.S. Food and Drug Administration. (2015). Zurampic (lesinurad) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2017). Duzallo (lesinurad and allopurinol) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Ironwood Pharmaceuticals. (2017-2019). Annual reports and filings concerning Duzallo. Ironwood Pharmaceuticals.
